Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy
Open Access
- 4 February 2018
- journal article
- case report
- Published by Elsevier BV in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 2 (1), 74-77
- https://doi.org/10.1016/j.mayocpiqo.2017.12.001
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint InhibitorsJournal of Thoracic Oncology, 2017
- PD-1 Checkpoint Inhibitor Associated Autoimmune EncephalitisCase Reports in Oncology, 2017
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals Of Oncology, 2015
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals Of Oncology, 2015
- Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case reportBMC Research Notes, 2015
- Ipilimumab-Induced Encephalopathy with a Reversible Splenial LesionCancer Immunology Research, 2015
- Infections of the CerebellumNeurologic Clinics, 2014
- Paraneoplastic syndromes of the CNSThe Lancet Neurology, 2008
- Current Therapies for Paraneoplastic Neurologic Syndromes.Current Treatment Options in Neurology, 2003
- Paraneoplastic Cerebellar Ataxia Due to Autoantibodies against a Glutamate ReceptorNew England Journal of Medicine, 2000